1036756-15-6

Basic information

• Product Name: 2(1H)-Quinazolinone, 6-bromo-8-fluoro-
• Synonyms: 2(1H)-Quinazolinone, 6-bromo-8-fluoro-;6-bromo-8-fluoroquinazolin-2-ol;6-BROMO-8-FLUORO-2(1H)-QUINAZOLINONE
• CAS NO: 1036756-15-6
• Molecular Formula: C₈H₄BrFN₂O
• Molecular Weight: 243.0325632
• Mol File: 1036756-15-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2(1H)-Quinazolinone, 6-bromo-8-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinazolinone, 6-bromo-8-fluoro-(1036756-15-6)
• EPA Substance Registry System: 2(1H)-Quinazolinone, 6-bromo-8-fluoro-(1036756-15-6)

Safety Data

• Hazardous Substances Data: 1036756-15-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2(1H)-Quinazolinone, 6-bromo-8-fluorois used as a key intermediate in the synthesis of pharmaceuticals for its potential antitumor activity. It is particularly valuable for the development of new drugs targeting cancer treatment due to its ability to inhibit cell proliferation and induce apoptosis in cancer cells.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2(1H)-Quinazolinone, 6-bromo-8-fluorois utilized as a promising candidate for further research and development. Its unique chemical structure allows for the exploration of its pharmacological properties and potential applications in the creation of novel bioactive compounds.
Used in Drug Design and Development:
2(1H)-Quinazolinone, 6-bromo-8-fluorois employed in drug design and development processes to create new therapeutic agents. Its presence in the quinazolinone family of compounds provides a foundation for the modification and optimization of its properties to enhance its efficacy as an antitumor agent.
Used in Cancer Treatment:
As an antitumor agent, 2(1H)-Quinazolinone, 6-bromo-8-fluorois used in cancer treatment to target and inhibit the growth of cancer cells. Its role in inducing apoptosis makes it a potential therapeutic option for various types of cancer, offering a new avenue for cancer therapy.

Upstream product

• 57-13-6 urea 
• 825-22-9 3-fluoroanthranilic acid 
• 874784-14-2 2-amino-5-bromo-3-fluorobenzoic acid 
• 906811-50-5 (2-amino-5-bromo-3-fluorophenyl)methanol 
• 953039-26-4 2-amino-5-bromo-3-fluorobenzoic acid hydrobromide 

Downstream Products

• 953039-25-3 6-bromo-2-chloro-8-fluoroquinazoline 

Relevant articles and documents

COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.

TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating fibrosis in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating fibrosis

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.

QUINAZOLINES FOR PDK1 INHIBITION

The invention provides novel quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.